Biomarkers of insulin resistance and their performance as predictors of treatment response

in overweight adults.

RJ Brogan[1,2], O Rooyackers[3], BE Phillips[4], B Twelkmeyer[3], LM Ross[5], PJ Atherton[4], WE

Kraus[5], JA Timmons[2,6*] and IJ Gallagher[7*]

Author byline

Robert James Brogan, Olav Rooyackers, Bethan E Phillips, Brigitte Twelkmeyer, Leannna M Ross,

Phillip James Atherton, William E Kraus, James Arthur Timmons, Iain James Gallagher.

10
11

Affiliations

[1]Anaesthesia, Pain and Perioperative Medicine, Fiona Stanley Hospital, Perth, WA, Australia

[2]Augur Precision Medicine LTD, Stirling, Scotland

[3]Division of Anesthesiology and Intensive Care, CLINTEC, Karolinska Institutet, Sweden

[4]Clinical, Metabolic and Molecular Physiology Research Group, School of Medicine, University

of Nottingham, Derby, England

[5]Duke University School of Medicine, Durham, NC, USA

[6]Faculty of Medicine and Dentistry, Queen Mary University of London, London, England

[7]Center for Biomedicine and Global Health, Edinburgh Napier University, Edinburgh, Scotland

* Senior Authors

Key words: T2DM, Insulin resistance, biomarkers, regression, Bayesian projective prediction

Corresponding author: j.timmons@qmul.ac.uk, ORCID ID 0000-0002-2255-1220

Disclosure summary

There are no financial conflicts of interest to disclose. JT is a major shareholder in Augur

Precision Medicine (APM) LTD, a bioinformatics company, and there is no commercial links

between APM and the present study.

Funding statement

The clinical data utilised in this study was funded by multiple sources: European Union Seventh

Framework Programme (META-PREDICT, HEALTH-F2-2012-277936); STRRIDE II

(NCT00275145) by NHLBI grant HL-057354 and STRRIDE-PD (NCT00962962) by NIDDK

DK-081559 and R01DK081559. The data modelling was supported by Augur Precision

Medicine LTD.

Abstract

Insulin Resistance (IR) contributes to the pathogenesis of type 2 diabetes mellitus (T2DM), and

is a risk factor for cardiovascular and neurodegenerative diseases. Amino acid and lipid

metabolomic biomarkers associate with future T2DM risk in epidemiological cohorts. Whether

these biomarkers can accurately detect changes in IR status following treatment is unclear.

Herein we evaluated the performance of clinical and metabolomic biomarkers to predict altered

IR following lifestyle-based interventions. First, we evaluated the performance of two distinct

insulin assay types (high-sensitivity ELISA and Immunoassay) and built cross-sectional clinical

and metabolomic IR diagnostic models. These were utilised to stratify IR status in pre-

intervention fasting samples, from three independent cohorts (META-PREDICT (MP, n=179),

STRRIDE-AT/RT (S-2, n=116) and STRRIDE-PD (S-PD, n=149)). Linear and Bayesian

projective prediction strategies were used to evaluate biomarkers for fasting insulin and

HOMA2-IR and change in fasting insulin with treatment. Both insulin assays accurately

quantified international standard insulin (R^2>0.99), yet agreement for fasting insulin was less

congruent (R^2=0.65). A mean treatment effect on fasting insulin was only detectable using an

ELISA. Clinical-metabolomic models were statistically related to fasting insulin (R^2 0.33-0.39)

with modest capacity to classify IR at a clinically relevant HOMA2-IR threshold. Furthermore,

no model predicted treatment responses in any cohort. Thus, we demonstrate that the choice of

insulin assay is critical when quantifying the influence of treatment on fasting insulin, while

none of the clinical-metabolomic biomarkers, established in cross-sectional data, are suitable for

monitoring longitudinally changes in IR status.

Introduction

Chronic hyperinsulinaemia, a feature of type 2 diabetes mellitus (T2DM), contributes to a cycle of events that may drive further insulin resistance (IR). [1] IR also appears to promote cardiovascular [2] and neurodegenerative diseases [3] while extreme IR represents a distinct category of T2DM [4]. Lifestyle-based treatments are effective at reducing the risk of developing T2DM. [5–8] Such programs typically include prescription of physical activity and modify IR with high intra-individual variability. [9–14] Similar variability in IR responses to drug treatment also occur. [15,16] While monitoring the efficacy of any treatment on blood glucose is straightforward [17], the same cannot be said for monitoring insulin action. [18,19] Furthermore, the varying characteristics of commonly used insulin assays complicate comparisons across studies [20,21] while routine measurement of IR in clinical practice are considered too complex and costly. Established clinical definitions exist for T2DM and impaired glucose tolerance (IGT), but the definition of IR is less well developed. This is problematic because IR is distinct from IGT and may precede T2DM by decades. There is therefore a requirement to develop suitable technologies for diagnosing and tracking IR. [22,23] These IR biomarkers should offer practical (e.g. cost, simplicity) advantages over laboratory insulin assays. If such biomarkers can be shown to accurately predict longitudinal changes in IR, then efforts to configure low-cost standardised assays from minimally invasive sampling could be beneficial.

Interest in identification of robust and cost-effective IR diagnostics has led to the development of several clinical [24] and molecular prototypes including assays that measure branched-chain amino acids (BCAA)[25–28], plasma lipoproteins[29–31] and multi-protein signatures[32] all of which correlate with IR status in cross-sectional or epidemiological cohorts. Useful biomarkers of IR should also reliably identify when a treatment for IR is ineffective, to allow the patient to be offered an alternative treatment. [14–16,33,34] There have been attempts to establish if plasma BCAA abundance tracks treatment responses yielding conflicting conclusions, partly because the studies were too small to reliably explore such relationships. [35,36] Determinants of insulin action combine multiple factors, including acute signalling mechanisms in the hours post-treatment (e.g. exercise) as well as more stable long-term adaptive changes [37] – such as increased tissue vascularisation. [38] Immediately post-exercise insulin action and glucose tolerance can be impaired, while insulin

responses to an oral glucose tolerance test (OGTT) appear lowest 72hr following the previous

exercise training session.[39] Such temporal influences have not been considered when evaluating

the available IR biomarkers and here we measured IR status within 24hr and 48-72hr of the final

exercise training session. In the present study, we evaluated, in hundreds of individuals at-risk

for T2DM, the performance of established BCAA and lipid biomarkers, combined with simple to

measure clinical phenotypes to estimate fasting IR and predict changes in insulin following

supervised lifestyle interventions.[9,12,40,41] We established that choice of insulin assay is critical

for capturing interactions with exercise status and, using Bayesian projective prediction, that

robust plasma biomarkers of IR status in cross-sectional and prospective studies are unable to

predict treatment responses following exercise-training based treatments.

Materials and Methods

Clinical Cohorts

A useful molecular biomarker should be able to track insulin resistance status and changes with a

clinical intervention, regardless of the nature of the intervention. In the present modelling we

contrast diverse life-style interventions in multiple studies, with comparable metabolic health and

sedentary behaviours and comparable treatment effects. The META-PREDICT study was

approved by local ethics committees at all trial centres (the University of Nottingham Medical

School Ethics Committee: D8122011 BMS; the Regional Ethical Review Board Stockholm:

2012/753-31/2; the ethics committee of the municipality of Copenhagen and Frederiksberg in

Denmark: H-3-2012-024; Comite etico de Investigacion Humana de la ULPGC: CEIH-2012-02;

and the Loughborough University Ethics Approvals Human Participants Sub-Committee:

12/EM/0223). All complied with the 2008 Declaration of Helsinki. Both STRRIDE I and AT/RT

study protocols were approved by the institutional review boards at Duke University and East

Carolina University. The STRRIDE-PD study protocol was approved by the institutional review

board at Duke University. All participants provided both verbal and signed written informed

consent.

META-PREDICT (MP) cohort: This consisted of 189 active participants, recruited as

previously described from 5 geographical regions across Europe.[12] All clinical methods relied on

cross-site standard operating procedures (SOPs), while insulin and metabolomic measures were

performed in a single central laboratory. All participants were classified as sedentary (<600

metabolic equivalents (METs) min·wk^{-1}) using a modified International Physical Activity

Questionnaire,[42] and had a fasting blood glucose level consistent with World Health

Organisation (WHO) criteria for impaired fasting glucose (6.1 - 6.9 mmol·l^{-1}), and/or a BMI >27

kg·m^{-2}. Participants were excluded if they had evidence of active cardiovascular,

cerebrovascular, respiratory, gastrointestinal or renal disease or had a history of malignancy,

coagulation dysfunction, musculoskeletal or neurological disorders, recent steroid or hormone

replacement therapy, or any condition requiring long-term drug prescriptions. Exercise training

was supervised and consisted of three high intensity cycling sessions (5-by-1 minute at 125%

VO_2 max) per week for 6 weeks.[12] Prior to the baseline assessments, participants were instructed

to refrain from exercise for three days. Supine blood pressure (Omron M2, Omron Healthcare,

Kyoto, Japan) and resting heart rate (RHR) were determined as the average of three consecutive

measurements.

STRRIDE AT/RT (S2) cohort (NCT00275145): This study examined the independent and

combined effects of aerobic and resistance exercise on cardiometabolic health in sedentary,

overweight or obese adults with mild to moderate dyslipidaemia (LDL 3.37-4.92mmol/l or HDL

≤1.03mmol/l in males and ≤1.16mmol/l in females). Participants were randomized to one of

three groups for eight months: 1) aerobic training only: 14 KKW at 65-80% VO_{2peak}; 2)

resistance training only: 3 days/week, 8 exercises, 3 sets/exercise, 8-12 repetitions/set; 3) full

combination of the aerobic and resistance training programs. [41]

STRRIDE PD (S-PD) cohort (NCT00962962): This study enrolled older sedentary, overweight

or obese adults without or without impaired fasting glucose into one of four intervention groups

for six months: 1) low amount/moderate intensity (10 KKW at 40-55% $VO_{2reserve}$): 2) high

amount/moderate intensity (16 KKW at 40-55% $V\square O_{2researve}$); 3) high amount/vigorous intensity

(16 KKW at 65-80% $VO_{2reserve}$); 4) clinical lifestyle prescription, which included low

amount/moderate intensity exercise of 10 KKW at 40-55% $VO_{2reserve}$ plus diet to achieve 7%

body weight loss (comparable to the Diabetes Prevention Program (DPP). [40]

Plasma sample glucose and insulin analysis

Blood glucose was analysed using a YSI 2300 STAT Plus glucose analyser (Yellow Springs Inc.

Ohio, USA) in MP and S2, and with a Beckman-Coulter DxC600 clinical analyzer (Brea, CA,

USA) in S-PD. The samples from all cohorts were analysed using high sensitivity insulin ELISA

(Dako A/S, Sweden). Two levels of QC solutions were run for insulin. Coefficients of variation

(CV) were acceptable; 4.68-8.03 % on both levels. In MP we also used an automated analyser

(Immulite 2000) for analyses of insulin during an oral glucose tolerance test. To assure

comparability of the results, we independently checked the assay performance for cross detection

of insulin and C-peptide. The WHO standard for insulin and C-peptide were obtained from

NIBSC (The National Institute for Biological Standards and Control). A dilution series for both

analytes was prepared and run on Dako ELISA and Immulite 2000. The diluted WHO insulin

standards were subjected to the same procedure as the samples.

Plasma sample metabolomic analysis

Metabolomic analyses for MP has not been previously published (other than fasting glucose and

insulin). Samples were randomized for sample preparation and analyses resulting in an equal

distribution of all centres and possible responders and non-responders. We used hierarchical

clustering of metabolomic variables to evaluate if there was an obvious systematic centre

specific bias (**Figure S3**)**.** Samples were taken after an overnight fast as arterialized venous

blood and run in duplicate. Results within ±20% CV were accepted and if this limit was not met,

the sample was rerun. Quality controls (QC) were run for all analyses and with each batch of

sample preparation to ensure stable performance of the analysis procedure. QC for all analyses

included in house controls made from pooled EDTA plasma from healthy controls. The

following methods were used for each metabolite. Sample analysis used a Konelab 20XTi

photospectrometer (Thermo Fisher Scientific, Thermo Electron Oy, Vantaa Finland) for high

density lipoprotein HDL cholesterol, LDL cholesterol and triacylglycerides (TAG). Amino acids

were analyzed using HPLC 2695 (Waters, Watford, UK) with online derivatization and a

fluorescence detector 474 (Waters, Watford, UK) using a method described previously.[43,44] Fatty

acids were analyzed using ultra-high performance liquid chromatography (Ultimate 3000

UHPLC, Thermo Fisher Scientific, Germering, Germany) coupled to a TSQ Vantage with

electrospray ionization (ESI) and triple quadrupole mass spectrometer (MS/MS) (Thermo Fisher

Scientific, San Jose, CS, USA). For the STRRIDE cohorts, samples were analysed for plasma

glucose concentration at the research site (Duke University, USA) using a Beckman–Coulter

DxC600 clinical analyser (Brea, CA, United States). Plasma samples were analysed on 400 MHz

nuclear magnetic resonance (NRM) profilers at LipoScience, now LabCorp (Morrisville, NC,

United States), as previously described [45]. The lipoprotein parameters and the BCAA were

identified by retrospectively analysing digitally stored spectra using the newly developed NMR-

based lipoprotein LP4 algorithm, which correlate with mass spectrometry methods.[46]

As distinct methodologies were utilised for the metabolomic analyses between MP and

STRRIDE cohorts (e.g. mass spectroscopy versus NMR profiling) we explored the compatibility

of the metabolomic data common to our diagnostic models. For S2 and S-PD, both mass

spectroscopy and NMR methodologies were utilised for lipid related metabolomics and Bland-

Altman analysis was performed to assess measurement agreement between HDL and TAG

(**Figure S4-7**). There was high correlation between methods for HDL (S2 r^2 0.96, p<0.001; S-PD

r^2 0.89, p<0.001) (**Figure S4A**, **Figure S5A**) and TAG (S2 r^2 0.99, p<0.001; S-PD r^2 0.95,

p<0.001) (**Figure S6A, Figure S7A**). Bland-Altman analysis revealed a mean HDL

measurement error of -0.066 mmol/L in S2 (**Figure S4B**) and -0.064 mmol/L in S-PD (**Figure**

S5B) and mean TAG measurement error of +0.02mmol/L in S2 (**Figure S6B**) and +0.04mmol/L

in S-PD (**Figure S7B**) with 95% of observations within 1.96 standard deviation of mean. Work

by Wolak-Dinsmore *et al* demonstrated that NMR overestimates VAL and LEU by >25% (mean

value) and underestimates ILE by 10-15% (mean value). While MS was used in MP, S2 and S-

PD relied on NMR for BCAA quantification. [46] Based on these known systematic differences,

modelling was performed independently in each cohort, using cross-validation methods.

Statistical Modelling

Raw data from the clinical chemistry analyses was analysed with GraphPad Prism 5 (Software

MacKiev, 2007, version 5.01) and more advanced analysis was accomplished using

STATISTICA 10 (StatSoft Inc., 2011, version 10.0.228.2). All subsequent analysis was

performed in R versions 4.1.1 and 4.3.2. We utilised conventional and Bayesian strategies to

model data. Potentially predictive variables were selected based on known associations with IR

and T2DM. Linear regression modelling was applied to investigate associations between

dependent and independent variables. Briefly, after reducing each dataset to complete cases common variables were identified across all three cohorts. The criterion for considering a clinically useful variable was pragmatic – it had to be cheap and reliably measured in a primary care setting e.g. maximal aerobic capacity relates to IR status in some but not all cohorts, but it was not considered because of the time and cost required to measure it accurately. From the variables selected, some were dropped because of high collinearity (e.g. systolic blood pressure was retained in favour of diastolic blood pressure and mean arterial pressure in the Bayesian analysis). We removed participants with obesity class III (BMI >40kg/m^2) for the Bayesian analysis and all continuous variables were normalised. The latter steps were carried out using the tidymodels in R (10.32614/CRAN.package.tidymodels) [47] and applied consistently across all datasets. Collinearity between variables was checked for each dataset separately **(Figure S8)**. Apart from BCAA in the MP dataset, there were no pairwise correlations with an absolute value >0.5. Linear models were built with student-t priors on both the intercept and slope coefficient terms (df=3, mean=0 and scale=4). These were mildly informative on the scale of the normalised data. More details are provided in the supplementary material. We built Bayesian multivariable linear models using the brms package to predict change in circulating insulin using relevant clinical variables, circulating BCAA levels and selective lipids.[48] These full models were considered reference models. We then used projective prediction to identify a subset of variables with predictive performance as close as possible to that of the reference model.[49] Briefly, projective prediction first generates a solution path - the variable ranking - for each sub model examined. Then a leave-one-out cross-validation process determines the predictive performance of each sub model along the predictor ranking. Data and the analysis script can be found at 10.5281/zenodo.13850947. [50]

Results

Demographic, blood and metabolomic data for the three independent cohorts – MP, S2 and S-PD – are presented in **Table 1.**

Comparison of insulin assay and metabolomics assay performance

A long-standing challenge in studying the physiology of insulin is that commercial assays show

distinct specificity and sensitivity profiles, with no agreement to move to a single standard

assay.[20,21] Certain insulin assays, utilised in exercise intervention studies (e.g. HERITAGE)[51] or

included in genome-wide association modelling,[52] do not show molecular associations consistent

with modern high sensitivity assays.[13] In the present study we produced a large-scale comparison

of two typical insulin assays (Immulite 2000) and a high sensitivity ELISA kit (Dako,

Stockholm, Sweden), run concurrently in the same lab, on samples obtained before and after

exercise-training that reduced IR.[53] Both Immulite 2000 and Dako ELISA showed a strong

correlation between expected and measured insulin; $R^2=0.999$ and $R^2=0.992$, respectively

(International WHO standard for insulin, The National Institute for Biological Standards and

Control, **Figure S1**). No cross reaction between insulin and c-peptide standards was detected

(data not shown). When plotting both insulin values from the same fasting samples, there was

moderate agreement between the two assays ($R^2=0.65$, **Figure S2)**. Critically, using insulin

measurements from the high-sensitivity ELISA, we were able to detect a significant reduction in

IR following 6 weeks exercise, while the Immulite 2000 immune-assay was unable to detect a

change (**Figure 1**). All the subsequent analyses in this article relied on insulin values obtained

from the Dako high-sensitivity ELISA (produced in a single laboratory).

Biomarker association with fasting insulin and HOMA2-IR status

Potential predictor variables were selected based on the literature summarised above and

availability in all three cohorts. Univariable linear regression analysis was performed to explore

individual relationships between fasting insulin and the selected clinical and metabolomic

biomarkers (**Figure 2**; full results in **Table S1**). In MP, all pre-selected variables except age

(p=0.09) reached statistical significance for linear association with fasting insulin (age is a

reliable covariate but the age-range in MP was limited). In S2 $\log_{10}$ BMI (p<0.001), fasting

glucose (p<0.001), HDL (p=0.007), TAG (p<0.001) and amino acids (isoleucine (ILE)

p=0.0005, leucine (LEU) p=0.006, valine (VAL) p<0.001, alanine (ALA) p=0.0027) were

significant for a linear association with fasting insulin. Univariate associations were very similar

for S-PD except ALA (p=0.068). For subsequent integrated models and treatment responses

predictions, variables which showed a statistically significant association in one or more of the

cohorts were considered further (given each was already supported with previously published

evidence for having a cross-sectional association with IR status).

As each study used distinct metabolomic methods (see Methods) we performed multivariable

linear regression and logistic regression with K-fold cross validation (k=10) separately in each

cohort. **Table S2** demonstrates the same models discussed below, to predict fasting insulin using

K-fold cross validation multiple linear regression, with the combined model demonstrating the

strongest association with directly measured insulin (r^2 0.33 – 0.39). Fasting glucose was

excluded when using HOMA2-IR as the dependant variable due to its inclusion in the HOMA2-

IR model. To evaluate classification performance, cohorts were divided into insulin sensitive

(HOMA2-IR <1.3) and insulin resistant (HOMA2-IR ≥1.3) based on values obtained in a large

population study (n=95,540), where a HOMA2-IR ≥1.3 was associated with a hazard ratio of 3.2

(95% CI 1.9-5.3) for the development of T2DM over a median of 4.7y. [54] The non-diabetic

subjects in this study (n=93,710) are Caucasians living in Denmark. They were of similar age

and metabolic health to the STRRIDE cohorts described in this study (84.8% of S2 and 78.2% of

S-PD were Caucasian). The MP cohort are of the similar ethnicity and metabolic health to the

population study but were younger (median age 38 vs 57) with a higher BMI (median BMI 31 vs

26). Four models were assessed in each cohort (**Figure 3**); a baseline model (age, BMI and

gender), a BCAA model (age, BMI, gender and sum of BCAA), a lipid model (age, BMI,

gender, HDL, LDL and TAG) and finally, a combined model (age, BMI, gender, BCAA, HDL,

LDL and TAG). This allowed us to evaluate if lipids (HDL, LDL and TAG) and BCAA (ILE,

LEU and VAL) add value to risk estimation from simple clinical variables. The baseline

('clinical') model had no discriminatory performance in S-PD, so the addition of metabolomic

variables improved the model substantially. The statistical advantage of including metabolites in

the model applied to S-PD may reflect the more homogeneous nature of that cohort, for the

utilised clinical parameters. Otherwise, inclusion of BCCA and/or lipids offered no meaningful

value, with poor sensitivity (**Table 2**).

Biomarker based prediction of IR status in response to lifestyle intervention.

The results above established that each potential biomarker associates with fasting insulin in

some or all trials (**Table S1**) but that multivariable models do not identify *IR status* (based on a

HOMA2-IR threshold) in any cohort (**Figure 3, Table 2**). The utility of the same biomarkers for

predicting exercise treatment related insulin responses was now examined. For this we included

changes in fasting glucose (as it is easy and inexpensive to measure). **Figure 4** displays the

univariable linear relationships of changes in clinical and metabolomic biomarkers with changes

in fasting insulin as measured with the high sensitivity ELISA. **Figure S8** shows the same data

but displaying correlation coefficients (including individual amino acids). To further examine the

predictive utility of individual and combinations of biomarkers we built Bayesian linear models

independently for each cohort modelling change in circulating insulin after the exercise

interventions used. These models included age and changes over the intervention in individual

BCAA, fasting glucose, BMI, lipids, systolic blood pressure and alanine. The full models

("reference" models) were considered as the optimum solution, given the present data, to the

prediction task.[55] The posterior predictive distributions showed the models performed well (**Fig**

5A-C). Using projective prediction, we found that the biomarkers did not improve predictive

performance over a null model i.e. the intercept term (**Figure 5D-F**).[49] Thus, change in

biomarkers (alone or additively combined) did not predict change in insulin following an

exercise intervention.

Discussion

Development of robust and cost-effective diagnostics should contribute to combating the T2DM

epidemic and facilitate alignment of clinical practice with the recommendations of the

International Diabetes Federation, namely earlier detection and prevention of pre-diabetes.[56]

Insulin is not routinely measured in clinical practice and thus crucial information, regarding the

temporal characteristics of IR over disease development, is lacking. Previous work has identified

several potential biomarkers for IR in cross-sectional and prospective settings. [25–27,29–31,57] The

present study extends this body of work to evaluate these IR biomarkers in the context of

changes in circulating insulin in response to life-style intervention, including exercise training.

Importance of the insulin assay

To our knowledge we are the first to study the importance of insulin assay performance on

tracking insulin changes in response to exercise interventions. The MP cohort represents typical

younger-middle aged individuals with multiple risk factors for T2DM.[12] We found that the

Immulite 2000 immunoassay was unable to detect changes in fasting insulin status following

supervised exercise training.12 In contrast, concurrent measurements using a high sensitivity

ELISA assay detected a significant reduction in fasting insulin. Neither assay demonstrated any

cross-reactivity with c-peptide and a strong correlation with the WHO standard. The American

Diabetes Association has attempted to promote a consensus on standardizing the measurement of

insulin.[20,21] Our analysis indicates that when environmental influences are to be considered a

high-sensitivity ELISA insulin assay must be utilised. We have previously observed that some

older insulin assays, with unclear specificity[58] were unsuitable for genomic association

analysis.[13] Indeed, it is plausible that the use of insulin assays insensitive to variations within the

'normal' range, or with some specificity for C-peptide, limited genome-wide association

modelling of fasting insulin.[59] While suboptimal insulin assays will not be voluntarily retired by

manufacturers, it would seem sensible that the research community adopt the use of a limited

number of high-sensitivity assays for studies of fasting insulin in most situations[20,21] especially

when subtle gene-environment interactions are being modelled.

Metabolomic components of the IR biomarker models

There is a well-established positive correlation between individual blood BCAA and IR. [25–27] As

such, pathways that control BCAA catabolism have gained interest as possible targets for

reversing IR.[28,60,61] Furthermore, BCAA have been combined with clinical parameters to increase

the performance of models that predict both IR and risk of T2DM.[29,31,57] We previously

identified, in four independent cohorts, a transcriptional signature including genes controlling

BCAA catabolism pathways, that related to IR after adjustment for age, VO2max and BMI

(n=564). We also found that in response to four independent lifestyle interventions (n=196),

expression of 16 genes in human skeletal muscle changed in proportion to improvements in

insulin sensitivity, with 25% of these related to BCAA metabolism.[13] By mass, skeletal muscle

has the largest capacity for BCAA catabolism in humans supporting the plausibility of these

observations.[62]

We found plasma BCAA were unable to predict changes in IR status in the present study. Insulin

mediated BCAA clearance, however, may rely on other organs including the liver meaning that

blood levels may not accurately reflect metabolism of BCCA.[63] In a recent study, Lee et al

reported that baseline plasma BCAA levels related to change in glucose infusion rate during a

hyperinsulinaemic–euglycaemic clamp as a measure of insulin sensitivity and liver fat content.[36]

This association occurred despite no change in total plasma BCAA levels and a reported increase

in muscle BCAA catabolism pathway gene expression. We also found no change in BCAA

levels with any exercise training protocol (**Table 1**), which might be understandable as only

~40% of subjects demonstrate a numerical improvement in HOMA2-IR while some demonstrate

an increase in IR.[12,13] Our observations are consistent with earlier distinct modelling approaches

applied to the STRRIDE cohorts where the combination of BCAA and lipid-based IR biomarkers

did not reliably detect changes in insulin sensitivity produced by a combination of resistance and

aerobic training.[17] Various other combinations of BCAA and protein metabolites have been

considered in IR models and while some variation is observed,[64] these are likely random

associations found in small cohorts. Using energy restriction to modify IR, we recently reported

that group mean differences in plasma BCAA abundance were unchanged, despite group mean

improvements in IR. [64] These observations contrast with a previous study, relying on a sample

size 10 times smaller, where changes in plasma BCAA abundance *did* track with improved IR

status.[35]

In the present analysis we considered several strategies, including several distinct clinical and

metabolomic variables, to model both fasting insulin and HOMA2-IR. A practical approach

would combine informative but easy to measure (cost effective) clinical variables with

metabolomic markers (that could be measured in the future using cost-effective devices).

Bayesian modelling and projective prediction [65,66] was used to establish a sparse model that

retained the ability to provide useful predictions of circulating insulin changes. Projective

prediction uses the predictions from the reference (full) model to identify a subset of variables

with predictive ability as close as possible to that of the full model. This was unable to identify a

smaller set of variables (or indeed any variables) useful for predicting change in circulating

insulin after lifestyle intervention using this strategy. Conventional regression modelling, against

changes in HOMA2-IR also failed to identify a useful model.

Clinical evaluation of IR biomarker models

Diagnosing IR is challenging not least because the definitions of being "IR" remains imprecise.
The gold standard method is commonly claimed to be the 'clamp' technique or intravenous
glucose tolerance test (IGTT).[19,67] However, this requires substantial resources and therefore the
IGTT is rarely used for diagnosis. The 'clamp' by its nature is non-physiological (e.g.
individuals can be exposed to non-physiological conditions). Alternative indices of IR and
pancreatic beta cell function exist and include the homeostatic model assessment (HOMA) and
HOMA2 [68,69], Matsuda index [70] and the disposition index (DI).[71] These indices are also not used
widely, again largely because insulin is not routinely measured, a fact that in turn prevents
establishment of reliable thresholds for diagnosis of IR. Although several epidemiological
studies have used HOMA and HOMA2, there is limited modelling to define a clinically useful
cut-off value for IR. Several of these studies used a percentile cut off and then applied ROC
analysis to determine the threshold for a diagnosis of IR. This was then related to relative risk for
relevant clinical outcomes e.g. progression to T2DM or cardiovascular disease. As a result, the
HOMA-IR threshold reported to define 'at risk' varies from 1.8 to 3.9 depending on cohort
characteristics and methods used.[18] One very large study estimated that a HOMA2-IR in excess
of 1.3 represented a hazard ratio of >3.2 for developing T2DM over an average of ~5 years in
95,450 subjects.[54] This is the largest study linking a particular HOMA2-IR value to incipient
diabetes and we used this HOMA2-IR cut-off in the present study. Interestingly, in exploratory
analysis we conducted, 83% of those with the most severe IR (HOMA2-IR $\geq$ 2.4) were not
classified as metabolically compromised based on fasting glucose or 2-hour-glucose OGTT data.
This illustrates that the current reliance on glucose-centric risk assessment limits our ability to
identify (and hence intervene) in those people with IR. Nevertheless, all surrogate variables
investigated in the present study had only a modest ability to diagnose IR in a cross-sectional
setting, and no ability to track changes in IR with exercise or diet. Thus, new large-scale trials,
where IR is treated by various means, and insulin and biomarker measurements are made, are
urgently required.
432
In summary, we evaluated multiple novel predictive models for IR, including models
incorporating cholesterol species and BCAA. These models failed to predict change in IR status
following supervised lifestyle modification using multiple interventions. A main limitation of our
study is the limited availability of common metabolomic variables across cohorts. Nevertheless,

we are not aware of any blood based metabolic disease biomarkers that sensitively track

improvements in insulin sensitivity across multiple independent cohorts.

Data Availability Statement

A majority of the datasets generated during and/or analyzed during the current investigation are

not publicly available but are available from the corresponding author on reasonable request.

Funding

The clinical data utilised in this study was funded by multiple sources: European Union Seventh

Framework Programme (META-PREDICT, HEALTH-F2-2012-277936); STRRIDE II

(NCT00275145) by NHLBI grant HL-057354 and STRRIDE-PD (NCT00962962) by NIDDK

DK-081559 and R01DK081559.

Contributors

RJB, JAT, OR and IJG conceptualized aims and designed the analysis strategy. All authors

contributed to data collection and/or pre-processing. RJB and IJG performed data analysis and

JAT contributed to interpretation. JAT and RJB wrote the first draft and JAT, RJB and IJG

produced a full manuscript. All authors contributed to revision of manuscript and have read and

approved the final manuscript.

References

1.　Cen HH, Hussein B, Botezelli JD, et al. Human and mouse muscle transcriptomic

analyses identify insulin receptor mRNA downregulation in hyperinsulinemia-associated

insulin resistance. *FASEB Journal*. 2022;36(1).

2.   Wamil M, Coleman RL, Adler AI, McMurray JJV, Holman RR. Increased Risk of

Incident Heart Failure and Death Is Associated With Insulin Resistance in People With

Newly Diagnosed Type 2 Diabetes: UKPDS 89. *Diabetes Care*. 2021;44(8):1877-1884.

3.   Folch J, Olloquequi J, Ettcheto M, et al. The Involvement of Peripheral and Brain Insulin

Resistance in Late Onset Alzheimer's Dementia. *Front Aging Neurosci*. 2019;11:236.

4.   Dennis JM, Shields BM, Henley WE, Jones AG, Hattersley AT. Disease progression and

treatment response in data-driven subgroups of type 2 diabetes compared with models

based on simple clinical features: an analysis using clinical trial data. *Lancet Diabetes*

Endocrinol. 2019;7(6):442-451.

5.   Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and

weight loss in the Diabetes Prevention Program Outcomes Study. *Lancet*.

2009;374(9702):1677-1686.

6.   Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle

intervention in type 2 diabetes. *New England Journal of Medicine*. 2013;369(2):145-154.

7.   Uusitupa M, Peltonen M, Lindström J, et al. Ten-year mortality and cardiovascular

morbidity in the Finnish Diabetes Prevention Study - Secondary analysis of the

randomized trial. *PLoS One*. 2009;4(5):1-8.

8.   Hivert MF, Christophi CA, Franks PW, et al. Lifestyle and metformin ameliorate insulin

sensitivity independently of the genetic burden of established insulin resistance variants in

diabetes prevention program participants. *Diabetes*. 2016;65(2):520-526.

9.   Ross LM, Slentz CA, Kraus WE. Evaluating Individual Level Responses to Exercise for

Health Outcomes in Overweight or Obese Adults. *Front Physiol*. 2019;10.

10.   Huffman KM, Slentz CA, Bateman LA, et al. Exercise-induced changes in metabolic

intermediates, hormones, and inflammatory markers associated with improvements in

insulin sensitivity. *Diabetes Care*. 2011;34(1):174-176.

11.   AbouAssi H, Slentz CA, Mikus CR, et al. The Effects of Aerobic, Resistance and

Combination Training on Insulin Sensitivity and secretion in Overweight Adults from

STRRIDE AT/RT: A Randomized Trial. *J Appl Physiol (1985)*. 2015;118(12)1474-1482.

12.   Phillips BE, Kelly BM, Lilja M, et al. A practical and time-efficient high-intensity interval

training program modifies cardio-metabolic risk factors in adults with risk factors for type

II diabetes. *Front Endocrinol (Lausanne)*. 2017;8:229.

13.   Timmons JA, Atherton PJ, Larsson O, et al. A coding and non-coding transcriptomic

perspective on the genomics of human metabolic disease. *Nucleic Acids Res*.

2018;46(15):7772-7792.

14.   Álvarez C, Ramírez-Campillo R, Ramírez-Vélez R, Izquierdo M. Effects and prevalence

of nonresponders after 12 weeks of high-intensity interval or resistance training in women

with insulin resistance: a randomized trial. *J Appl Physiol*. 2017;122:985-996.

15.   Sears DD, Hsiao G, Hsiao A, et al. Mechanisms of human insulin resistance and

thiazolidinedione-mediated insulin sensitization. *Proc Natl Acad Sci U S A*.

2009;106(44):18745-18750.

16.   Brivba M, Ansone L, Silamikelis I, et al. Whole-blood transcriptome profiling reveals

signatures of metformin and its therapeutic response. *PLoS One*. 2020;15(8):e0237400.

17.   Ross LM, Slentz CA, Zidek AM, et al. Effects of Amount, Intensity, and Mode of

Exercise Training on Insulin Resistance and Type 2 Diabetes Risk in the STRRIDE

Randomized Trials. *Front Physiol*. 2021;12:1-10.

18.   Tang Q, Li X, Song P, Xu L. Optimal cut-off values for the homeostasis model

assessment of insulin resistance (HOMA-IR) and pre-diabetes screening: Developments in

research and prospects for the future. *Drug Discov Ther*. 2015;9(6):380-385.

19.   Ferrannini E, Mari A. How to measure insulin sensitivity. *J Hypertens*. 1998;16(7):895-

906.

20.   Manley SE, Stratton IM, Clark PM, Luzio SD. Comparison of II human insulin assays:

Implications for clinical investigation and research. *Clin Chem*. 2007;53(5):922-932.

21.   Miller WG, Thienpont LM, Van Uytfanghe K, et al. Toward standardization of insulin

immunoassays. *Clin Chem*. 2009;55(5):1011-1018.

22.   Thambisetty M, Metter EJ, Yang A, et al. Glucose intolerance, insulin resistance, and

pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging.

JAMA Neurol. 2013;70(9):1167-1172.

23.   Rodríguez-Mañas L, Angulo J, Carnicero JA, El Assar M, García-García FJ, Sinclair AJ.

Dual effects of insulin resistance on mortality and function in non-diabetic older adults:

findings from the Toledo Study of Healthy Aging. *Geroscience*. 2022;44(2):1095-1108.

24.   Clausen JO, Borch-Johnsen K, Ibsen H, et al. Insulin sensitivity index, acute insulin

526   response, and glucose effectiveness in a population-based sample of 380 young healthy

527   Caucasians: Analysis of the impact of gender, body fat, physical fitness, and life-style

528   factors. *Journal of Clinical Investigation*. 1996;98(5):1195-1209.

529   25.   Zheng Y, Ceglarek U, Huang T, et al. Weight-loss diets and 2-y changes in circulating

530   amino acids in 2 randomized intervention trials. *American Journal of Clinical Nutrition*.

531   2016;103(2):505-511.

532   26.   Shah SH, Bain JR, Muehlbauer MJ, et al. Association of a peripheral blood metabolic

533   profile with coronary artery disease and risk of subsequent cardiovascular events. *Circ

534   Cardiovasc Genet*. 2010;3(2):207-214.

535   27.   Bloomgarden Z. Diabetes and branched-chain amino acids: What is the link? *J Diabetes*.

536   2018;10(5):350-352.

537   28.   Newgard CB, An J, Bain JR, et al. A branched-chain amino acid-related metabolic

538   signature that differentiates obese and lean humans and contributes to insulin resistance.

539   *Cell Metab*. 2009;9(4):311-326.

540   29.   Floegel A, Stefan N, Yu Z, et al. Identification of serum metabolites associated with risk

541   of type 2 diabetes using a targeted metabolomic approach. *Diabetes*. 2013;62(2):639-648.

542   30.   Shalaurova I, Connelly MA, Garvey WT, Otvos JD. Lipoprotein insulin resistance index:

543   a lipoprotein particle-derived measure of insulin resistance. *Metab Syndr Relat Disord*.

544   2014;12(8):422-429.

31. Flores-Guerrero JL, Gruppen EG, Connelly MA, et al. A newly developed diabetes risk

index, based on lipoprotein subfractions and branched chain amino acids, is associated

with incident type 2 diabetes mellitus in the prevend cohort. *J Clin Med*. 2020;9(9):1-17.

32. Zanetti D, Stell L, Gustafsson S, et al. Plasma proteomic signatures of a direct measure of

insulin sensitivity in two population cohorts. *Diabetologia*. 2023;66(9):1643-1654.

33. Mutch DM, Temanni MR, Henegar C, et al. Adipose gene expression prior to weight loss

can differentiate and weakly predict dietary responders. *PLoS One*. 2007;2(12).

34. Newton RL, Johnson WD, Larrivee S, et al. A Randomized Community-based Exercise

Training Trial in African American Men: Aerobic Plus Resistance Training and Insulin

Sensitivity in African American Men. *Med Sci Sports Exerc*. 2020;52(2):408-416.

35. Glynn EL, Piner LW, Huffman KM, et al. Impact of combined resistance and aerobic

exercise training on branched-chain amino acid turnover, glycine metabolism and insulin

sensitivity in overweight humans. *Diabetologia*. 2015;58(10):2324-2335.

36. Lee S, Gulseth HL, Langleite TM, et al. Branched-chain amino acid metabolism, insulin

sensitivity and liver fat response to exercise training in sedentary dysglycaemic and

normoglycaemic men. *Diabetologia*. 2021;64(2):410-423.

37. Dimenna FJ, Arad AD. The acute vs. chronic effect of exercise on insulin sensitivity:

nothing lasts forever. *Cardiovasc Endocrinol Metab*. 2021;10(3):149-161.

38. Zheng C, Liu Z. Vascular function, insulin action, and exercise: an intricate interplay.

Trends Endocrinol Metab. 2015;26(6):297-304.

39.   King DS, Baldus PJ, Sharp RL, Kesl LD, Feltmeyer TL, Riddle MS. Time course for

exercise-induced alterations in insulin action and glucose tolerance in middle-aged people.

J Appl Physiol (1985). 1995;78(1):17-22.

40.   Slentz CA, Bateman LA, Willis LH, et al. Effects of exercise training alone vs a combined

exercise and nutritional lifestyle intervention on glucose homeostasis in prediabetic

individuals: a randomised controlled trial. *Diabetologia*. 2016;59(10):2088-2098.

41.   Slentz CA, Bateman LA, Willis LH, et al. Effects of aerobic vs. resistance training on

visceral and liver fat stores, liver enzymes, and insulin resistance by HOMA in overweight

adults from STRRIDE AT/RT. *Am J Physiol Endocrinol Metab*. 2011;301(5):1033-1039.

42.   Hagströmer M, Oja P, Sjöström M. The International Physical Activity Questionnaire

(IPAQ): a study of concurrent and construct validity. *Public Health Nutr*. 2006;9(6):755-

762.

43.   Godel H, Graser T, Földi P, Pfaender P, Fürst P. Measurement of free amino acids in

human biological fluids by high-performance liquid chromatography. *J Chromatogr A*.

1984;297:49-61.

44.   Vesali RF, Klaude M, Rooyackers O, Wernerman J. Amino acid metabolism in leg muscle

after an endotoxin injection in healthy volunteers. *Am J Physiol Endocrinol Metab*.

2005;288:360-364.

45.   Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic

resonance spectroscopy. *Clin Lab Med*. 2006;26(4):847-870.

46.   Wolak-Dinsmore J, Gruppen EG, Shalaurova I, et al. A novel NMR-based assay to

586   measure circulating concentrations of branched-chain amino acids: Elevation in subjects

587   with type 2 diabetes mellitus and association with carotid intima media thickness. *Clin*

588   *Biochem*. 2018;54:92-99.

589   47.   Kuhn M, Wickham H. Tidymodels: a collection of packages for modeling and machine

590   learning using tidyverse principles. Published 2020. Accessed April 04, 2025.

591   https://www.tidymodels.org

592   48.   Bürkner PC. brms: An R package for Bayesian multilevel models using Stan. *J Stat Softw*.

593   2017;80.

594   49.   Piironen J, Paasiniemi M, Vehtari A. Projective inference in high-dimensional problems:

595   Prediction and feature selection. *Electron J Stat*. 2020;14(1):2155-2197.

596   50.   Gallagher I, Timmons J, Brogan R. Biomarkers of insulin resistance and their

597   performance as predictors of treatment response in adults with risk factors for type 2

598   diabetes. *Zenodo*. Accessed April 04, 2025 https://doi.org/10.5281/zenodo.13819578

599   51.   An P, Teran-Garcia M, Rice T, et al. Genome-wide linkage scans for prediabetes

600   phenotypes in response to 20 weeks of endurance exercise training in non-diabetic whites

601   and blacks: The HERITAGE Family Study. *Diabetologia*. 2005;48(6):1142-1149.

602   52.   Bouchard C, Rankinen T, Timmons JA. Genomics and genetics in the biology of

603   adaptation to exercise. *Compr Physiol*. 2011;1(3):1603-1648.

604   53.   Phillips BE, Kelly BM, Lilja M, et al. A practical and time-efficient high-intensity interval

605   training program modifies cardio-metabolic risk factors in adults with risk factors for type

606   II diabetes. *Front Endocrinol (Lausanne)*. 2017;8(SEP).

607   54.   Marott SCW, Nordestgaard BG, Tybjaerg-Hansen A, Benn M. Causal associations in type

608   2 diabetes development. *Journal of Clinical Endocrinology and Metabolism.*

609   2019;104(4):1313-1324.

610   55.   Pavone F, Piironen J, Bürkner PC, Vehtari A. Using reference models in variable

611   selection. *Comput Stat*. 2023;38(1):349-371.

612   56.   *IDF Strategic Plan*.; 2023.

613   57.   Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing

614   diabetes. *Nat Med*. 2011;17(4):448-453.

615   58.   Keller P, Vollaard NBJ, Gustafsson T, et al. A transcriptional map of the impact of

616   endurance exercise training on skeletal muscle phenotype. *J Appl Physiol*.

617   2011;110(1):46-59.

618   59.   Manning AK, Hivert MF, Scott RA, et al. A genome-wide approach accounting for body

619   mass index identifies genetic variants influencing fasting glycemic traits and insulin

620   resistance. *Nat Genet*. 2012;44(6):659-669.

621   60.   Crossland H, Smith K, Idris I, Phillips BE, Atherton PJ, Wilkinson DJ. Exploring

622   mechanistic links between extracellular branched-chain amino acids and muscle insulin

623   resistance: an in vitro approach. *Am J Physiol Cell Physiol*. 2020;319(6):C1151-C1157.

624   61.   Roth Flach RJ, Bollinger E, Reyes AR, et al. Small molecule branched-chain ketoacid

625   dehydrogenase kinase (BDK) inhibitors with opposing effects on BDK protein levels. *Nat*

626   *Commun*. 2023;14(1).

627   62.   Sitryawan A, Hawes JW, Harris RA, Shimomura Y, Jenkins AE, Hutson SM. A molecular

628   model of human branched-chain amino acid metabolism. *Am J Clin Nutr*. 1998;68(1):72-

629   81.

630   63.   Shin AC, Fasshauer M, Filatova N, et al. Brain Insulin Lowers Circulating BCAA Levels

631   by Inducing Hepatic BCAA Catabolism. *Cell Metab*. 2014;20(5):898-909.

632   64.   Sayda MH, Abdul Aziz MH, Gharahdaghi N, et al. Caloric restriction improves glycaemic

633   control without reducing plasma branched-chain amino acids or keto-acids in obese men.

634   *Sci Rep*. 2022;12(1).

635   65.   Pavone F, Piironen J, Bürkner PC, Vehtari A. Using reference models in variable

636   selection. *Comput Stat*. 2023;38(1):349-371.

637   66.   Piironen J, Paasiniemi M, Vehtari A. Projective inference in high-dimensional problems:

638   Prediction and feature selection. *https://doi.org/101214/20-EJS1711*. 2020;14(1):2155-

639   2197.

640   67.   Tripathy D, Cobb JE, Gall W, et al. A novel insulin resistance index to monitor changes in

641   insulin sensitivity and glucose tolerance: The ACT NOW study. *Journal of Clinical*

642   *Endocrinology and Metabolism*. 2015;100(5):1855-1862.

643   68.   Wallace TM, Levy JC, Matthews DR, Homa T. Use and Abuse of HOMA Modeling.

644   *Diabetes Care*. 2004;27(6):1487-1495.

69.   Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA)

evaluation uses the computer program. *Diabetes Care*. 1998;21(12):2191-2192.

70.   Matsuda M, Defronzo RA. Insulin Sensitivity Indices Obtained From Comparison with

the euglycemic insulin clamp. *Diabetes Care*. 1999;22(9):1462-1470.

71.   Utzschneider KM, Prigeon RL, Faulenbach M V., et al. Oral Disposition index predicts

the development of future diabetes above and beyond fasting and 2-h glucose levels.

Diabetes Care. 2009;32(2):335-341.

Figure Legends

Figure 1. Insulin assay statistical performance for identifying a statistically significant difference

in pre vs post exercise training samples from all included exercise protocols. Fasting insulin

(pmol/L) was measured using a high sensitivity ELISA (right) and the Immulite 2000 automated

analyser (left). P-values are calculated from paired t-tests on log10 fasting insulin (pmol/L).

Figure 2. Scatter plots with OLS line of best fit (95% CI shaded) between log10 fasting insulin

and clinical and metabolic variables. A) MP, B) S2 and C) S-PD

Figure 3. Utility of baseline c linical and metabolomic variables to classify HOMA2-IR status at

1.3 unit threshold reflecting the analysis of Marott et al.[55] K-fold cross validation logistic

regression ROC curves for A. MP, B. S2 and C. S-PD.

Figure 4. Scatter plots with OLS line of best fit (95% CI shaded) between delta fasting insulin
and clinical and metabolic variables. A) MP, B) S2 and C) S-PD

Figure 5. Left panel; Posterior predictive distributions for A. MP, B. S2 and C. S-PD. Right
panel; Expected log predictive density (Elpd, upper trace) and root mean square error (RMSE,
lower trace) for D. MP, E. S2 and F. S-PD. Elpd and RMSE are shown with 95% nominal
coverage intervals.

Figure S1. Performance of the insulin assays. A) Immulite using titration international insulin
standard, B) ELISA using titration international insulin standard, and C) Immulite vs ELISA
standard curve values using international insulin standard once converted to uIU/ml.

Figure S2. Correlation of participant fasting insulin measured using Dako ELISA and Immulite
2000 assays.

Figure S3. Hierarchical clustering of subjects by their metabolomic profile demonstrating that
there is no centre specific bias. Copenhagen (CPH), Las Palmas (LPA), Loughborough (LU),
Stockholm (Stock).

Figure S4. S2 HDL assay performance. A) Comparison of mass spectroscopy and nuclear
magnetic resonance (NMR) measurement of HDL using linear regression. B) Bland-Altman plot

to estimate of bias with 95% confidence interval shown in blue, with upper (green) and lower

(red) limits.

Figure S5. S-PD HDL assay performance. A) Comparison of mass spectroscopy and nuclear

magnetic resonance (NMR) measurement of HDL using linear regression. B) Bland-Altman plot

to estimate of bias with 95% confidence interval shown in blue, with upper (green) and lower

(red) limits.

Figure S6. S2 TAG assay performance. A) Comparison of mass spectroscopy and nuclear

magnetic resonance (NMR) measurement of TAG using linear regression. B) Bland-Altman plot

to estimate of bias with 95% confidence interval shown in blue, with upper (green) and lower

(red) limits.

Figure S7. S-PD TAG assay performance. A) Comparison of mass spectroscopy and nuclear

magnetic resonance (NMR) measurement of TAG using linear regression. B) Bland-Altman plot

to estimate of bias with 95% confidence interval shown in blue, with upper (green) and lower

(red) limits.

Figure S8. Correlation plots showing strength of correlation between the variables used in the

generation of linear models to predict change in circulating insulin across lifestyle interventions.

A. MP, B. S2 and C. S-PD

Tables

Table 1. **Demographics. Median and IQR.** All available samples were utilised for baseline

modelling. In each analysis, only subjects with complete data were used in the pre/post

modelling, resulting in ~ 20% fewer subjects than recruited or completing the intervention.

Table 2 - K-fold cross validation logistic regression model statistics for combined model

predicting insulin resistance (HOMA2 IR ≥1.3) using age, BMI, gender, sum of branched chain

amino acids, HDL, LDL and triglycerides.

Table S1. Linear regression modelling using log10 fasting insulin as dependant variable. Note

the sample sizes reflecting all subjects with data for each individual clinical parameter or

metabolomic measure. In final integrated modelling only subjects with all completes values were

included.

Table S2. K-fold cross validation multiple linear regression predicting baseline $\log_{10}$ fasting

insulin from clinical and metabolomic variables

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Table 1.

	MP		S2		S-PD	
	Pre	**Post**	**Pre**	**Post**	**Pre**	**Post**
N	**179**	**109**	**116**	**85**	**149**	**122**
Gender (f:m)	100:79	58:51	58:58	43:41	89:60	71:51
Age	38 (18)	38 (18)	50 (14.5)	50 (17)	59 (11)	59 (12)
Weight (kg)	91.5 (20.1)	91.6 (21)	88 (17.5)	85.5 (13.2)	86.2 (17.4)	83.7 (16.5)
BMI	31 (5.5)	30.6 (4.766)	30.4 (4.88)	30 (5)	30.2 (4.45)	29.4 (4.6)
SBP	125 (14)	121 (16)	119 (16)	121 (18)	126 (16)	122 (21)

(mmHg)						
DPB (mmHg)	78 (13)	77 (14)	80 (14)	80 (14)	75 (12)	72 (13)
MAP (mmHg)	94 (13)	90 (12)	93 (15)	80 (14)	91 (13)	89 (13)
Resting HR	70 (12)	68 (12)	74 (16)	NA	NA	NA
VO2 max (mL/min/kg)	27.5 (10)	30.2 (11)	26.7 (7.56)	30.7 (9.6)	23.8 (7.05)	26 (8.25)
Fasting glucose (mmol/L)	4.61 (0.43)	4.6 (0.4)	5.26 (0.65)	5.33 (0.77)	5.78 (0.78)	5.81 (0.74)
2-hour glucose (mmol/L)	6.67 (1.51)	6.32 (1.9)	NA	NA	7.66 (3.43)	7.22 (2.3)
Fasting insulin (imm)	84.4 (65.4)	78.7 (51.7)	55.7 (43.7)	44.3 (33.5)	236 (234)	195 (199)
Fasting insulin (ELISA)	57.7 (42.5)	50.9 (37.6)	30.7 (43.7)	36.6 (33.2)	49.6 (58.4)	40.3 (47.2)
HOMA2 IR	1.2 (0.9)	1.07 (0.8)	1.07 (1)	0.81 (0.71)	1.12 (1.3)	0.95 (1.07)
Sum BCAA (µmol/L)	424 (133)	438 (139)	424 (90.4)	465 (85.5)	439 (99.1)	429 (96.1)
Leucine (µmol/l)	120 (40.6)	126 (39)	153 (36.2)	171.7 (39.5)	148 (37.9)	148 (35.1)
Isoleucine (µmol/L)	62.89 (22.6)	63.8 (21.7)	66.8 (20.1)	65.6 (22.5)	62.8 (19.7)	59.8 (14.5)
Valine (µmol/l)	239 (70.2)	247 (75.5)	208 (51.8)	230 (50)	221 (50.2)	220 (49.5)
HDL (mmol/L)	1.02 (0.39)	1.04 (0.4)	0.9 (0.33)	1.12 (0.33)	1.06 (0.39)	1.11 (0.37)
LDL (mmol/L)	2.64 (0.99)	2.5 (0.96)	2.45 (0.87)	2.72 (0.75)	3.12 (0.96)	2.96 (0.82)
TAG (mmol/L)	1.17 (0.75)	1.09 (0.72)	1.4 (0.85)	1.25 (0.78)	1.3 (0.83)	1.18 (0.95)
ALA (µmol/L)	321 (107)	326 (127)	419 (110)	405 (150)	399 (98)	390 (123)

Table 2.

	MP	S2	S-PD
Accuracy (95% CI)	0.676 (0.602-0.744)	0.707 (0.615-0.788)	0.644 (0.562-0.721)
Kappa	0.339	0.347	0.27
Sensitivity	0.58	0.512	0.563
Specificity	0.755	0.822	0.706
PPV	0.662	0.629	0.59
NPV	0.685	0.741	0.682
Prevalence	0.453	0.371	0.43
Detection rate	0.263	0.19	0.242